The Current Ratio as of November 2024 (TTM) for Talaris Therapeutics, Inc. (TALS) is 18.64

According to Talaris Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 18.64. This represents a change of 11.54% compared to the average of 16.71 of the last 4 quarters.

Talaris Therapeutics, Inc. (TALS) Historical Current Ratio (quarterly & annually)

How has TALS Current Ratio performed in the past?

The mean historical Current Ratio of Talaris Therapeutics, Inc. over the last ten years is 27.29. The current 18.64 Current Ratio has changed 6.73% with respect to the historical average. Over the past ten years (40 quarters), TALS's Current Ratio was at its highest in in the June 2021 quarter at 58.03. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Talaris Therapeutics, Inc. (TALS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Talaris Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Talaris Therapeutics, Inc. (TALS) Average Current Ratio

How has TALS Current Ratio performed in the past?

The current Current Ratio of Talaris Therapeutics, Inc. (TALS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Talaris Therapeutics, Inc. (TALS) Current Ratio vs. Peers

How is TALS’s Current Ratio compared to its peers?

Talaris Therapeutics, Inc.’s Current Ratio is less than Edgewise Therapeutics, Inc. (26.35), greater than Adicet Bio, Inc. (10.64), less than Cullinan Oncology, Inc. (24.46), greater than Vor Biopharma Inc. (4.69), greater than CytomX Therapeutics, Inc. (1.04), greater than Instil Bio, Inc. (12.90), greater than Neoleukin Therapeutics, Inc. (15.33), greater than Spero Therapeutics, Inc. (2.68), greater than Assembly Biosciences, Inc. (2.36), greater than Nuvation Bio Inc. (9.57), greater than Achilles Therapeutics plc (6.04), greater than NextCure, Inc. (9.07), greater than Ovid Therapeutics Inc. (5.66), greater than Connect Biopharma Holdings Limited (12.04),

Build a custom stock screener for Talaris Therapeutics, Inc. (TALS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Talaris Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Talaris Therapeutics, Inc. (TALS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Talaris Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.